<SEC-DOCUMENT>0001193125-19-289153.txt : 20191112
<SEC-HEADER>0001193125-19-289153.hdr.sgml : 20191112
<ACCEPTANCE-DATETIME>20191112062119
ACCESSION NUMBER:		0001193125-19-289153
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20191111
FILED AS OF DATE:		20191112
DATE AS OF CHANGE:		20191112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		191205834

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 5
		STREET 2:		20 GEORGE STREET
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 5
		STREET 2:		20 GEORGE STREET
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d76834d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of November, 2019 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia
Therapeutics Limited </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9745;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F&nbsp;&nbsp; &#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if
the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule
101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by
check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>:
Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which
the registrant is incorporated, domiciled or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on
EDGAR. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp; No&nbsp;&nbsp;&#9745; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If
&#147;yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b) </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Kazia Therapeutics Limited</B> <B></B>(Registrant) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Kate Hill </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kate Hill </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company Secretary </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date 11 November 2019 </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g76834g0223114724363.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX RELEASE </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11 November 2019
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF MEETING FOR AN EXTRAORDINARY GENERAL MEETING </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sydney, 11 November 2019</B> &#150; Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to
provide a Notice of Meeting in respect of an Extraordinary General Meeting, to be held at 11am on Friday 20 December 2019 at the offices of Computershare Investor Services, Level 3, 60 Carrington Street, Sydney, NSW 2000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please visit our website <U>https://www.kaziatherapeutics.com/</U> to access materials relevant to the EGM and also to register your vote online. The EGM page
will be live on the website from Wednesday 13 November, after the conclusion of our AGM. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We ask that investors register their intention to attend the EGM
so that we can properly cater for the event. You are also welcome to submit questions in advance of the meeting &#150; all of these activities can be managed via our website. We look forward to welcoming shareholders to the EGM. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[ENDS] </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Kazia Therapeutics Limited
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline
includes two clinical-stage drug development candidates, and we are working to develop therapies across a range of oncology indications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead program
is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma multiforme, the most common and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late 2016,
GDC-0084 entered a phase II clinical trial in 2018. Initial safety data was released in May 2019, and efficacy data is expected in 2H 2019. GDC-0084 was granted orphan designation for glioblastoma by the US FDA in February 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TRX-E-002-1 (Cantrixil), is a third-generation benzopyran molecule with activity against cancer stem cells and is being developed to treat ovarian cancer.
TRX-E-002-1 is currently undergoing a phase I clinical trial in Australia and the United States. Initial data was presented at the AACR annual conference in April 2019 and the study remains ongoing. Cantrixil was granted orphan designation for
ovarian cancer by the US FDA in April 2015. </P> <P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><B>Board of Directors</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Mr Iain Ross </B>Chairman,<B> </B>Non-Executive Director </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Mr
Bryce Carmine </B>Non-Executive Director </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Mr Steven Coffey </B>Non-Executive Director </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Dr James Garner </B>Chief Executive Officer, Managing Director </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>KAZIA THERAPEUTICS LIMITED </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ABN 37 063 259 754 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>THE MATTERS RAISED IN THIS DOCUMENT WILL AFFECT YOUR SHAREHOLDING IN THE COMPANY. YOU ARE ADVISED TO READ THIS DOCUMENT IN ITS ENTIRETY
BEFORE THE EXTRAORDINARY GENERAL MEETING REFERRED TO BELOW IS CONVENED. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>IF YOU ARE IN ANY DOUBT ABOUT THE ACTION YOU SHOULD
TAKE IN RESPONSE TO THIS DOCUMENT, PLEASE CONSULT YOUR STOCKBROKER, SOLICITOR, ACCOUNTANT OR OTHER PROFESSIONAL ADVISER. </I></B></P> <P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g76834g04q07.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF EXTRAORDINARY GENERAL MEETING, </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>EXPLANATORY STATEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>AND </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>PROXY FORM
</B></P> <P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">THIS IS A NOTICE OF AN EXTRAORDINARY GENERAL MEETING OF THE COMPANY TO BE HELD AT<B> 11AM&nbsp;ON&nbsp;FRIDAY&nbsp;20&nbsp;DECEMBER
</B><B>2019</B> AT THE OFFICES OF COMPUTERSHARE INVESTOR SERVICES, LEVEL&nbsp;3,&nbsp;60&nbsp;CARRINGTON&nbsp;STREET,&nbsp;SYDNEY NSW&nbsp;2000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A PROXY FORM FOR USE AT THIS MEETING IS INCLUDED WITH THIS DOCUMENT. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">TO BE VALID, PROXY FORMS MUST BE COMPLETED AND RETURNED TO THE COMPANY&#146;S SHARE REGISTRY, COMPUTERSHARE, BY<B> NO LATER THAN
11AM&nbsp;(SYDNEY&nbsp;TIME)&nbsp;ON&nbsp;18&nbsp;DECEMBER&nbsp;2019.</B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11&nbsp;November 2019 </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Fellow Shareholder </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are pleased to invite you to attend
an Extraordinary General Meeting of the Shareholders of Kazia Therapeutics Limited, which is scheduled to be held at Level&nbsp;3, 60&nbsp;Carrington Street, Sydney NSW&nbsp;2000 on Friday 20&nbsp;December 2019 at 11&nbsp;am (Sydney time). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Enclosed with this letter is the Notice of Meeting, which details the items of business to be dealt with at the Meeting. We hope you will consider the matters
presented to you in this Notice and support us in our endeavours to continue to grow the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The full range of R&amp;D activities of the Company is
presented on the Kazia website which can be found at (<U>www.kaziatherapeutics.com</U>). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>AGENDA </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The resolutions on the agenda for this Meeting are to ratify the previous issue of Shares as part of the Company&#146;s recent Share placement to professional
and sophisticated investors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>VOTING </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you plan to
attend the Meeting, please bring a copy of the enclosed Proxy Form with you to facilitate registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are unable to join us, you are encouraged
to appoint a proxy to attend and vote on your behalf. To be valid for the purposes of the Meeting, Proxy Forms must be completed and returned as instructed in this Notice of Meeting, by no later than 11.00&nbsp;am (Sydney time) on Wednesday
18&nbsp;December 2019. Full instructions for voting by proxy are detailed on the back of the Proxy Form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Your vote is important and we encourage you
to either attend the Meeting in person or complete the Proxy Form accompanying this Notice and return it to the Company or the Share Registry in accordance with the directions provided. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yours faithfully </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g76834sig.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kate Hill </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company Secretary
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On behalf of the Board of Directors </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF EXTRAORDINARY GENERAL MEETING </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ABN 37 063 259 754 </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Time and Place of
Meeting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOTICE </B>is hereby given that an Extraordinary General Meeting of Kazia Therapeutics Limited ABN&nbsp;37 063&nbsp;259&nbsp;754
(<B>Company</B>) will be held at the following time and location, and at that Meeting the business specified below will be conducted. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Date:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Friday 20 December 2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Time</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">11.00 am (Sydney time)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Location</B>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Computershare Investor Services, Level&nbsp;3, 60&nbsp;Carrington Street, Sydney NSW&nbsp;2000</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Business </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>RESOLUTION 1 &#150; RATIFICATION OF PREVIOUS ISSUE OF SHARES UNDER LISTING RULE 7.1 PLACEMENT CAPACITY AS PART OF A SHARE PLACEMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To consider and, if thought fit, to pass the following resolution as <B>an Ordinary Resolution</B>: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Resolution 1 &#150; Ratification of previous issue of Shares to sophisticated and professional investors under the Company&#146;s 15%
placement capacity under Listing Rule 7.1 as part of a Share placement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;That for the purposes of ASX Listing Rule&nbsp;7.4 and
for all other purposes, Shareholders ratify the issue and allotment of 9,250,000 Shares to sophisticated and professional investors at an issue price of $0.40 per Share, which were issued under the Company&#146;s 15% placement capacity under Listing
Rule&nbsp;7.1, as further described in the Explanatory Memorandum.&#148; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>RESOLUTION 2 &#150; RATIFICATION OF PREVIOUS ISSUE OF SHARES UNDER
LISTING RULE 7.1A PLACEMENT CAPACITY AS PART OF A SHARE PLACEMENT </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To consider and, if thought fit, to pass the following resolution as <B>an Ordinary
Resolution</B>: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Resolution 2 &#150; Ratification of previous issue of Shares to sophisticated and professional investors under the
Company&#146;s 10% placement capacity under Listing Rule&nbsp;7.1A as part of a Share placement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>&#147;That for the purposes of ASX
Listing Rule 7.4 and for all other purposes, Shareholders ratify the issue and allotment of 750,000 Shares to sophisticated and professional investors at an issue price of $0.40 per Share, which were issued under the Company&#146;s 10% additional
placement capacity under Listing Rule&nbsp;7.1A, as further described in the Explanatory Memorandum.&#148; </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To transact any other business as may be brought before the Meeting in accordance with the Constitution of the Company and of which the requisite notice has
been given. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>By order of the Board </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g76834sig.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kate Hill </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company Secretary
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: 11&nbsp;November 2019 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notes: </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Shareholder who is entitled to attend and cast a vote at the Meeting is entitled to appoint a proxy.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The proxy need not be a Shareholder of the Company. A Shareholder who is entitled to cast two or more votes may
appoint two proxies and may specify the proportion or number of votes each proxy is appointed to exercise. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If you wish to appoint a proxy and are entitled to do so, then complete the attached proxy form in accordance
with the instructions on the form and return the completed proxy form to the Share Registry in a manner indicated on the form no later than 11 am (Sydney time) on Wednesday 18 December 2019. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the proxy has two or more appointments that specify different ways to vote on the resolution the proxy must
not vote on a show of hands. If the proxy is the Chair of the Meeting, the proxy must vote on a poll or must vote the way specified in the proxy form. If the proxy is not the Chair of the Meeting the proxy need not vote on the poll, but if the proxy
does so, the proxy must vote as specified in the proxy form. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the proxy form specifies the way the proxy is to vote on a particular resolution and the proxy is not the
Chair of the Meeting and a poll is demanded and either the proxy is not recorded as attending, or the proxy does not vote, the Chair of the Meeting is deemed the proxy for that resolution. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A corporation may elect to appoint a representative, rather than a proxy, under the Corporations Act, in which
case the Company will require written proof of the representative&#146;s appointment which must be lodged with or presented to the Company before the General Meeting. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company has determined under regulation 7.11.37 of the <I>Corporations Regulations 2001</I> (Cth) that for
the purpose of voting at the General Meeting or adjourned meeting, securities are taken to be held by those persons recorded in the Company&#146;s register of Shareholders as at 7:00pm (Sydney time) on Wednesday 18 December 2019.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If you have any queries on how to cast your votes, please call the Company&#146;s share registry, Computershare
Investor Services Pty Limited, on 1800 783 447 (within Australia) or +61 3 9473 2555 (outside Australia) during business hours. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Exclusion Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="73%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Resolution 1: Ratification of Previous Issue of Shares under Listing Rule&nbsp;7.1 placement capacity</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Company will disregard any votes cast in favour of Resolution&nbsp;1 by or on behalf of any person who participated in the issue of Shares the subject of this Resolution&nbsp;1 and any Associate of those persons.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Resolution 2: Ratification of Previous Issue of Shares under Listing Rule&nbsp;7.1A placement capacity</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Company will disregard any votes cast in favour of Resolution&nbsp;2 by or on behalf of any person who participated in the issue of Shares the subject of this Resolution&nbsp;2 and any Associate of those
persons.</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, the Company need not disregard a vote cast on Resolutions 1 or 2 if: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is cast by a person as a proxy for a person who is entitled to vote, in accordance with the directions on the
proxy form; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is cast by the Chair of the Meeting as proxy for a person who is entitled to vote, in accordance with a
direction on the proxy form to vote as the proxy decides. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EXPLANATORY STATEMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Explanatory Statement is included in and forms part of the Notice of Meeting. It contains an explanation of, and information about, the Resolutions to be
considered at the Meeting. It is given to Shareholders to help them determine how to vote on the Resolutions set out in the Notice of Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shareholders should read this Explanatory Statement in full and, if in doubt about what to do in relation to a Resolution, Shareholders should consult their
stockbroker, solicitor or financial or other professional advisor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Business </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>(A)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Resolutions 1 and 2 &#150; Resolutions regarding the issue of Shares to sophisticated and professional
investors under the Placement</U> </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Background </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As announced to the ASX on 28&nbsp;October 2019, the Company undertook a placement of Shares under section&nbsp;708A of the Corporations Act to qualified
sophisticated and professional investors at $0.40 per Share to raise $4 million (before costs) (<B>Placement</B>). The issue price represented a discount of 14% to the closing price of the Company&#146;s Shares on 23&nbsp;October 2019 (being the
last closing price prior to the announcement of the Placement), </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Placement involved the issue of 10,000,000 Shares to qualified sophisticated and
professional investors under the Company&#146;s existing placement capacity under Listing Rules&nbsp;7.1 and&nbsp;7.1A. These Shares were issued on 1&nbsp;November 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Resolutions 1 and 2 seek approval from Shareholders under Listing Rule&nbsp;7.4 (and for all other purposes) to ratify the issue of the Shares. 9,250,000
Shares were issued under the Company&#146;s 15% placement capacity under Listing Rule&nbsp;7.1 and 750,000 Shares were issued under the Company&#146;s existing 10% additional placement capacity under Listing Rule&nbsp;7.1A, which was approved by
Shareholders at the Company&#146;s 2018 annual general meeting. The Company is also seeking Shareholder approval for the additional 10% placement capacity under Listing Rule&nbsp;7.1A at its 2019 Annual General Meeting, which will be held on
13&nbsp;November 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ratification of previous issue of Shares</B><B> (Resolutions 1 and 2)</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Listing Rule&nbsp;7.1, the Company is generally not permitted to issue more than 15% of its issued share capital in any 12-month period unless the issue
is approved by Shareholders or an exemption applies. However, Listing Rule&nbsp;7.4 provides that where a company ratifies an issue of securities, the issue is treated as having been made with approval for the purpose of Listing Rule&nbsp;7.1,
thereby replenishing the Company&#146;s 15% placement capacity and enabling it to issue further securities up to that limit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Listing
Rule&nbsp;7.1A, eligible entities may seek shareholder approval to issue up to 10% of the issued capital of the entity (within an existing class of quoted securities) within the 12 months from approval being granted. The Company received Shareholder
approval for the issue of securities under Listing Rule&nbsp;7.1A at its last annual general meeting, which was held on 8&nbsp;November 2018. The Company is also seeking Shareholder approval for the additional 10% placement capacity under Listing
Rule&nbsp;7.1A at its 2019 Annual General Meeting, which will be held on 13&nbsp;November 2019. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Listing Rule 7.4 also allows for issues under the
Company&#146;s existing 10% additional placement capacity under Listing Rule&nbsp;7.1A to be ratified, the effect of which will be that, if Resolution&nbsp;2 is passed, the Company will replenish its additional placement capacity under Listing
Rule&nbsp;7.1A. As the Company&#146;s additional placement was last approved at the Company&#146;s 2018 annual general meeting, the capacity will expire on 8&nbsp;November 2019, being the date that is 12 months from the date of that annual general
meeting. However, should Shareholders approve the Company&#146;s 10% additional placement capacity at its upcoming 2019 Annual General Meeting to be held on 13&nbsp;November 2019, subject to receiving Shareholder approval for resolution&nbsp;2, the
Company&#146;s additional 10% placement capacity will be replenished. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Resolutions 1 and 2 are approved by Shareholders, the Company will have capacity to issue the following
securities without Shareholder approval (calculated as at the date of the Meeting): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">10,825,001 securities under Listing Rule 7.1; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">7,216,667 Shares under the Company&#146;s additional placement capacity (assuming Resolution 4 at the upcoming
2019 Annual General Meeting is approved by Shareholders). </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information required under Listing Rule 7.4 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purposes of Listing Rule&nbsp;7.4, the Company provides the following information to Shareholders regarding the issue of the Shares as part of the
Placement: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shares issued as part of the Placement </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="73%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><B>Date of issue</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B></B>1 November 2019</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><B>Number and type of securities issues</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>10,000,000 Shares</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">9,250,000 Shares were issued under the Company&#146;s 15% placement capacity under Listing Rule&nbsp;7.1 and 750,000 Shares were issued under the
Company&#146;s existing 10% additional placement capacity under Listing Rule&nbsp;7.1A)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><B>Issue price per security</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$0.40 per Share</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><B>Terms of securities issued</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Shares issued rank pari passu with Shares then on issue</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><B>Persons to whom securities were issued</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B></B>Qualified institutional and sophisticated investors in Australia and internationally who participated in the Placement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><B>Intended use of funds</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B></B>Proceeds will be used to further the R&amp;D programs of the Company, and to fund working capital.</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Board recommendation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Directors unanimously recommend that Shareholders vote in favour of Resolution 1 and Resolution&nbsp;2. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.25in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>GLOSSARY </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purposes of this Document, the following terms have the meanings prescribed below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="73%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B></B>Australian dollars.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><B>2019 Annual General Meeting</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B></B>The annual general meeting of the Company to be held on 13&nbsp;November 2019.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><B>ASX</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">ASX Limited ACN 008 624 691 or the securities exchange market operated by it, as the context requires.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><B>Associate</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Has the meaning given to that term in sections&nbsp;10 to 17 of the Corporations Act.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><B>Board</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The board of Directors.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><B>Chair</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The person chairing the Meeting.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><B>Company</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Kazia Therapeutics Limited ACN 063 259 754.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><B>Constitution</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The constitution of the Company.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><B>Corporations Act</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B></B><I>Corporations Act 2001</I> (Cth).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><B>Director</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">A director of the Company.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><B>Explanatory Statement</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Explanatory Memorandum accompanying the Notice of Meeting.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><B>Listing Rules</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The listing rules of the ASX as amended from time to time.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><B>Meeting or General Meeting</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The general meeting of the Company to be convened by the Notice.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><B>Notice or Notice of Meeting</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The notice convening this Meeting of which the Explanatory Statement forms part.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><B>Placement</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The share placement conducted by the Company on 1&nbsp;November 2019, as described in section&nbsp;A of the Explanatory Memorandum.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><B>Proxy Form</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The proxy form attached to this Notice.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><B>Resolution</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">A resolution set out in the Notice.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><B>Share</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">A fully paid ordinary share in the issued capital of the Company.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><B>Share Registry</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Computershare Investor Services Pty Limited.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><B>Shareholder</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">A registered holder of one or more Share(s).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><B>Trading Day</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Has the meaning given to that term in Listing Rule&nbsp;19.12.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP><B>VWAP</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">In respect of a quoted class of equity securities (as that term is defined in Listing Rule&nbsp;19.12), the volume weighted average price of that class of equity securities sold on the ASX during the prescribed number of trading
days immediately preceding and including the date on which such price is to be determined, but does not include any transactions defined in the ASX Operating Rules as &#147;special&#148; crossings prior to the commencement of normal trading,
crossings during the after-hours adjust phase nor any overseas trades or trades pursuant to the exercise of options over ordinary shares in the capital of the Company.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g76834g0223114724363.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g76834g0223114724363.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !X QD# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=PISUXSCG)J+[5<^:TOVF;S&78S^8=Q7&,$YSC'&*.4.8V+K_DG-E_V%9_\
MT3'7IDQBO-+NI/E6YTSPZ4;U>*: $?DT;?G7D;ZDSZ##I/E*$BNGN1)GDEE5
M<8]/EJ#[7=98_:I\NGEM^\;YD_NGGD>W2AQN"E8]+O-, ^&LNA^=;&>TTV+4
MC L@\])=[/(2G7&QP,U-=?VE<:+8RR>=91PRZ<DUE*JO;R*7&R2W?^%C_$!S
MZUY=]JN?-:7[3-YK+L9_,.YEQC!.<D8[4ANK@QQQFXF,<1S&AD.U#ZJ,\?A1
MRAS'J'B2RO\ 68[JPU#SR\WB?R;$S@Y$)4[MF>=@'/'%:5]%:ZGXJ\,ZHTMG
M<06^I3V.ZWD#HJX+0*WHPQTKR!]0OI9HYI+VZ>6/[DC3,63Z$G(_"HA-*L1B
M6601E@Y0.0"PZ''K[TN0?.=WKD5]=:-X9?6["_O;YKJ[26,AEGD3=\J[L$]C
MCV!QQ4WPV^Q?V5JXU  VYO;(#=]T/O;9N_V=VW-<*^IZA(4,FH7;F,[D+3N=
MIZ9'/!J!9I4C>-)9%C<@NBL0&(Z9'?%/ETL+FUN>@Z"_B;2YM>UJX;4)IX+A
MX1:P[V6>\88W,J]55>>>/NBK6G6SS:AX3O)V1/L&C37DDDYVJKJS!2Q[?.1^
M5>>IJNI1,S1ZE>H7.6*W#@L?4\\G@5";NY92K7,Y4KL(,AP5SG'7IGG%'*',
M=+\0;?'B"#4!)#*NHVD5P9(&W(S@;7VGN,K^M<I3VED=$1Y'9(QA%9B0H] .
MU,JDK(EN["BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !3X8S-/'$&"EW"Y/09.*971Z!X<@U6Q>YGGD7YRBK'CC'<U<(.3LC.K4C3C
MS2)]4T)/#\$.I6=RYF@D4$2 88GT_P *S-2U>^UXQP^0H6/+!(@3D^IJ"Z-]
M=7W]G2W;W'E2&--S?+QQFK41D\/S'SE$T<R\%#@@CZ_6HQ%?EO"GN^AO@,![
M2U6N_=3UE;:_]?*Y2L]/N+^1T#;?*&"9">/:HFM+GSWMA&[M$>57) ]ZE_M2
MX6]FN82(S*>5QD>U3:?J[6DL[S(93,=Q(.#FN=NNKR23T6AW0A@I<L')K5WE
MTMK;3[B?_A);\:7_ &=MC'R^5YI!W!>F/Z9J]JOA:#3]':ZCN7:6( ONQM;/
M''YUERZ;<7D$NH_NU$F9!'WQ5K0[>;7I39W=]/\ 98$#B,-UYP,9]*ZZ-95;
MQ>KV]#R\7A)X5J:]V+UVW7]=/,P:*TM=TQ-)U(V\<A="@==W49[&LVE).+LQ
MPDIQ4ELSTKX>^ -(\4Z!-?:A+=K*ERT0$,@48 4^AYYKCF\/W%WXON-!TM&E
MD6ZDAC+]E5B-S'T &2:];^#/_(G7/_7Z_P#Z"E;6D>'[#P@NM:]>.&N+B66Y
MFE"D^7%N+!%[].3ZGZ"L.=ILZ%!-(X;Q1\/_  MX4\-->7EY?27I39"JR*!+
M+CLN/N]SSP*\JK=\6>)[KQ7K3WT^4@7*6T.>(T_Q/4G_  K"K2*:6IG)IO0*
M[;P!X'3Q:NHS73R1V\$?EQ.IQF8C(^H ZCW%<4JL[JB*6=B%51U)/05]*^&]
M.L_!OA?3M/N98XI'=4=C_P M)W/3\^![ 5-25EH5"-WJ?-US;36=U-:W"%)X
M7,<BGLP.#45>D?&#P]]@UR'6H$Q!?#9+@<"51U_%?_037F]5%W5R9*SL=!X)
MT.U\1^*[;3+UI5@D21F,3 -\JDCG!KU?_A37AG_GMJ7_ '_7_P")KPE69&#(
MS*PZ%3@BO4OA!HEQ?:C/KMW+.]O:YB@5Y&(:0CYCU[ X^I]JF=UK<J%MK$OC
M+X>>&/#'AFYU%9[_ .T#"6ZO,I#2'H,;>G4GV!KR>O0/BSXC_M;Q&-,@?-KI
MV5;'1I3][\AQ^=>?TX7MJ*=KZ'9?#KPII_BS4[ZWU%[A4@A5T\EPIR3CG(-9
MOC;0[7PYXKN=,LFE:WC2-E,K9;YE!/.!77_!/_D.:M_U[)_Z$:P_BI_R4*^_
MZY0_^@"DF^>PVER7.,H)P,T5U?P[\/\ _"0>+K=)4W6EI_I$^1P<'Y5_%L?@
M#5MV5R$KNQH>(OA])HG@73]:_>&\X-\A.0@?[N!VV\ _6N$KZHNQI^M1:AHL
MLB2GR@EQ$.J!P<?XBOF/5=-GT?5KK3;D?OK:0QD_WO0_B,'\:SIRON7.-MBG
M1116AF%%%% !1110 4444 %%%% !2J-SJOJ0*2G(0)$)Z!@3^= &GJNA2Z09
M%GG1I!<O!%&JG=*J$JT@]%W<#U.?2J2:??23/#'973S(,O&L+%E'J1C(KI=3
M\0:7JVOQ:I<FX$EO>G#(I4RVVXLAX/RNG3W&.<BG#7=/^W0W<>H20W-MIX@A
ME2V=4\[>Y+;02<*K9&>^,]*5V79',?8Y7$(@CFFDD0N46%LK@D'']X<=1TZ5
M9T338M7U.*QDO1:23,$B9H6<,Q/0XZ?6MG2]<TZU@L$FEF66VB"%_+9U.+EI
M"-H(R2I!!/ -9MCJ5M;>,HM4?>+1;\SG"_-LWD]/7!Z478K(B.D>;;75Q83M
M>16\L<?R0,K/N5B3MY( V&L\0RF SB*0P@[3)M.T'TSTS6SH6L0Z9#MDDE0G
M4;6X;RP>8XRY;_T(<=ZM2:[9OX=DLT.R;R9H-GD$[P\WF [MVU1C&>-V5&.*
M+L+(P/L5X'V&SN-^TOM\IL[1U.,=/>F?9YS!YX@E,/\ SUV';Z=>G6NNMO$U
MA_PE%_J5Q/<&.2\AEB+HS_NE;)7;N&&Z8SD#!JO-?V\/A> &XD)N+:^ACM@I
MVDO,,,><#&,].PQ1=A9'-?9KC]W_ */-^]&8_P!V?G_W?7\*E@TV^NH)YX+2
M62*"(32,%. A. ?<9_D?0UU4GBJP;4+&Y!=8UN4FDB2 @Q 0^6?F+'<>>B@#
M '>LU]4L!I[V,=U,5_LA+,2^40#(LWF=,YP1QGWHNPLC%DLY/.D2!)I@B!V8
M0L" 0#DCL.>O?K49@F$"SF&00L<+(4.TGT!Z5TSZ]932SE;R\M,R6TRRPQ_.
M_EP>64Z\?-T)XZU2N=4M9O#,5F9YGND2.-5"% H5F)5B#M=1GY3C<"3DXHNP
MLC/N-.:V_LXO*"M["LPVH24!=EQCN?ESQ4?V"Z9CY5K<2IO**ZPM\QSCTZ\=
M*V&O-,DBT*Z-](MQI\<4<EO]G8YVREB0^<=&_2K$OB.W-E<0Q3W"F2"[10 0
M-TER)%[_ -T=>QXHNPLC#M-*NK_$=I#-+<%G!B6(\!5W$[NF>O'7\Q5;R)A"
M9C#((E;:7*':&]">F?:NL_X233SJ4\OF3I%-J-U/N$9R(Y8/+5L9Z[N2*J1Z
M[:1^&H[(',T<#6[)Y)/FYF\S=N+8 (]MV1Z47861CS:9/;Z5%?S*T:R3F%8W
M0JQPH;=SV.ZJ5=#X@U:TO[-H[>ZN)WDU&:\Q+&5$:.J@*,D\@@CCBN>IH3"B
MBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7366A:G#H
M[7MM?M TD?F>2A(W+C/)]<5S-=)I;:_J.CR6UH\8M4'EAGP&(_N@UK2M?5'/
MB7)13325];F1I=G->7&^&41F/#;SS@TFIR737;1W<@9XN!M&!19&\M[_ ,B
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M%*^BWD-N9I1#$3,\"Q/*!*[H0&55ZG!(%7_M^F7/BG[?<R,($17#-"2LLZJ
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2\LN%RF<G.0?O'J*9#?6EFM^L$:S+)(C0+-&2  2>1GJ,TE&/5C<ZFJ2[?\
M!*L&FWESYGE0_P"J;8^Y@NUO3D]:A%M,8UD"'8TGE*<]6]/UK3LM1@:VNUO9
M5$T\XE+26_F@\'/'8\U'8W-D+1+>ZEEC\FY\]&2/=O& ,=>#P*.6(<\TW=%>
M'2KV=IECAR86*R NHVD=>IJNT$JQ)*4.QV**?4CJ/U%7%O8VGU.612INHW"
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
9HH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g76834g04q07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g76834g04q07.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M"EEP#3EAJD(\S0J>.HSERIFO7,=H4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % $<L\5NF^:5(UZ9=@!^
MM-1<M$B92C!7D[&=K,9U/0KA+)UE)P1L8$'!!Q6]%^RJIST.7$KVU"2INYP^
MGZ5?7%_%&D,L3;@2Y4C9COFO5J581BVV>!1P]6=1))K]#OM3TBUU6)4N%(9?
MNNG#"O(I5I4G>)]'7PT*ZM,?IVF6NEP>5;(1G[S$Y+?6IJ5957>0Z-"%"/+
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M5E4=W8TIJRN>E5D:A0!Q'Q8_Y$*Y_P"NL?\ Z%6E/XB*GPGC7@K_ )';1?\
MKZC_ )UO+X681W1].5R'4% !0!YO\7O$0L-"CT>%\7%\<R 'E8P?ZGC\#6M.
M-W<RJ.RL>("-S$TH1C&I"EL< G.!G\#^5=!@>M_!OQ$-MSX?G?!&9K?)_P"^
ME'Z'\ZPJQZFU-]#URL38S-:T:+6($5G\N6,DH^,_A6]"LZ+\CDQ6%CB(I/1H
MIZ)X:72KC[3+-YLV" %& *UKXGVJY4M#'"X%4)<[=V7/$.FR:OH=S91,%D<
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M@/#VK&PO'QI]XP#,3@1/T#?3L?S[5-2-U=%0E9V/?58,H92"I&01T-<QT"T
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M*+0H1<6>L5B:F!XTT_4M5\*7MCI)7[3, N&;;E<C< >W%5%I.[)DFU9'C/\
MPJGQ;_SXQ?\ ?]/\:W]I$Q]G(/\ A5/BW_GQB_[_ *?XT>TB'LY#X_A/XK>5
M4:U@C4G!=IUPON<<T>TB'LY'T"HPH'I7,= M ',^/=$O/$'A.XL+!5:X9T95
M9MH.&YYJX-)W9,E=61YOX7^&OB73O$^FWMW;11V]O.LCMYRG '/05I*<6K&4
M8-,]NK W"@#R+Q_X(\3^(_%4MY:V\4EHL:1PGSE!  R<@_[1-;0G&*L8SBVS
MIOAQX,F\*Z=<2WXC_M"Y8;@ASL0=%S]<DX]O2IG+FV+A'EW.WK,LY;Q[X6/B
MGP\;> (+V%A) S' SW&?0C]0*N$N5D3C='G?A7X?>+=$\3Z??M;QQ113+YK"
M=3^[)PPP#SQFM)3BU8SC"2=ST7QG;W$EM;R1@M#&3O [$XP<?G71@I14FGN<
M&9PG*,6MD9?A""<ZOYJHPB5"';''L*Z,9*/L[=3DRV$_:\RV.I\0::^KZ)<6
M43A)) -I8\9!!Y_*O$JPYX.*/J\'76'K1J-:(X_P]X.U*PUF&]O3%##;G>3O
M!)XKEI4)1ES2Z'MXS,J-6BZ=.[;.JL?%.D:C??8[:YS*<[<J0&^A-=,:T).R
M9X]7 8BC#GG'0V:U.(9++'!$TLKJD:#+,QP *3=M6.,7)\L5J8">(M'U])]*
M@NF62XC9%+(5SD8XK'VL*GNIGHO!XC"M5I1T33.2@^'VJF^6.9X5MPW,H;.1
M[#K7*L-.^I[,LXH*%XWOV/3CG:0#@]J]$^4/++FRNX+MX9HG\T-SP3D^OO7T
M$9QE&Z>A\A.E4C-QDM3T718)[71[:&X_UJKR/3G@?E7BUY*51N.Q]/A82A1C
M&>Y?K$Z H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * .>\1Z_-I4D=O;(OF.NXLW.!TX%=F&PZJIRD>;C<7*@U&"
MU8[PWKDVJB6*X51)$ =R\;A]*,305*SB/ XN5>\9[HTM7LFU'2+JS1]CRQE5
M)Z ^_M7!./-%H]C#U51JQJ-;,\YT;PAK"ZY#YUN88[>57:1CP0#GY?6N"G0G
MSZK8^FQ.8X?V#Y7=M;?YE_QYJVHVNKQ6T%Q-;PB(,/+<KN.3SQ]*TQ,Y*5DS
MGRG#T9TG.23=^I>T-M0\2>"KVUGE+2EBD<LA/S8P>3]>,U=/FJTFF<^*5+!X
MR,XK3=I&/H7@[5X]<MY;J'R(;>579]P.<'.!CK6-.A-33?0[<7F5!T'&#NVK
M'IU>B?*G%ZMXIOH=2E@MMD<<+E>5R6P>]>I1PD'!.74\+$8^K&HXPT2.DT74
MCJNFI<,@1\E6 Z9'I7#7I>RGRGJ86O[>FILT*Q.D* "@#%U#5[^RO4@33U=9
M7VQ,90-Q_I753HTYQNY;;Z'!6Q%6G-14-]M2Q>:E-8V%O/-; 2R2*C1[_NY]
M^]1"DIR:3T-:M>5*FI26K:1)>7YM;ZRMA'N^TLPW9QMP*F%/FC*78JI6Y)PA
M;XBM?ZM=6^J1V%I9K/(T7F<R;>Y']*TIT8RASR=C*MB)PJJE"-W:^Y/)?7-M
MH\MY<VHCFC!/E!\C\ZA4XRJ*$7H:2JSA1=2<;-="E#KURK6KWNG^3;W.!'*L
MFX9/3([5K+#QU4)7:,(XN:Y74A92V=S0U748]*L6N'&2#A5SC<?2L:5-U9<J
M.G$5U0ASLM0RK-"DJ'*.H8?0UFTXNS-8R4DI+J85OXBN72*XFT_99O)Y?FK)
MG:<XY'UKKEAHJ\5+7L>?#&S:4I0]UNU[ES4=3N;6^@M+6T6>252P!?;C%9TZ
M491<I.UC>M7G":A"-V_,FCN[M--GN;NU6&6)681B0-D 9ZBH<(N:C%W3+52H
MJ;G.-FO,AO=7-GI5O>B$,9B@V[L8W#/6JA1YYN%]B*N(]G2C4MO;\0UC4;O3
M8C-%9K- JY=S)MP<XZ44:<:CLW9AB:]2BN:,;KU%.HW,.CS7MS:".2,;A&),
MY'&#FCV<744(L?MIQHNI.-FNER1]5A@TB+4)U*K(BL$7DY(S@4E2;J."*>(C
M&BJLNMOQ(++4K^:XB6YTQX8I@2CAMVWO\WI53I0BGRRNT9TJ]64DIPLG_6HE
MWJ]RE_-:V=E]H-NH:3Y]IYYX'>G"C%Q4IRM<53$351PIQO;<UE)9%)4J2,X/
M45S/0[%JA:!A0 4 % !0 4 % !0 4 % &-K>@)K!CD$QBE0;0<9!%=-#$.CI
M:Z.'%8-8BSO9H@LM.A\+Z?<WDLC3/@;L#'?@#\35SJ/$S4%H9TJ,<#3E4;N4
M[3QF)+M4N;98HF.-X;.WW-:3P5HWB]3&GF:E.TXV1UE>>>P5+W2[#4MOVRTC
MF*?=++R/QJ90C+=&U*O5H_PY-$UO;0VD"P6\2Q1)]U$& *:2BK(B<Y3ES2=V
M1W]Y'I]E+=2 E8QG [GH!6E.#G)11SUJJI0<WT.9M_&KM<J+BU582<95CE?\
M:[Y8))>Z]3RH9HW*THZ%K4?",=[>O<Q71B\QMS*4W<GTY%9T\8X1Y6MC6MER
MJ3<XRM<V].L(M,LDMH22J\ECU)]:Y:E1U)<S.^C1C1@H1+59FP4 % &3JT$L
MNH:6\<;,L<V7(&=H]ZZ*,DH33[''B(2E4IM+9C?$EM+=:?%%$CL?/4G8,D#G
MFGAI*$VWV%C82G32BNJ*<FC/9ZQILD4MW<H';>96WA./IQ6BK*5.2:2,'AG3
MK0<6WOOK8CUZUFDUZ&80WK0B *7M1\P.3QFJP\DJ35U>_4C%TY.NI6=K=/F7
MIEDN/"TT4<-SO\LJ%F&9#SWK*+4:Z;:^6QT23EA6DG>W7<S[;3)[>[TEK@7-
MS;^6"8WRPA? QQV _2MI58RC/ELG^:.>G0E"=-RNU;[F7=4M;K4=4ACCA0V]
MLNX^<"$=CQCWP*RI3C3@VWJ^QOB*<ZU5)+2/?9DNA1W5FDNGW,;8A.8Y!DH5
M/8$^E37<9M3CU+PBG33I36VSZ%'1]">2TA>\EN%5)"_V9N%R#P<?K6M:NE)J
M"7J<^&PC<$ZC>^W0=XAMY9-3M)5ANVB5&#-:CY@?K2P\DH-77S'C(2=6+2=K
M=-S0M%:ZT.6W6*YB;8T0^U??.1U/Y_I64WRU5*Z^1TTTYT'!)K=:[F1-]MU*
MRLM,_L^>!HF3S)9%^0!1C@]ZZ(\E.4JG,F<4O:5H0H\C5K7;VT-G7XI)]#N8
MHD9W8#"J,D_,*YL.U&JFSNQD7*A)16H:I%))X?GB1&:0Q8"@9)-%)I54WW#$
M1<L.XI:V*EU87$_ARQCB3$]NL<GEMQDJOW?K6D*D8UI-[.YC4HSEAX);JS^Y
M;%FTU:XN;B.)M*N8<_?=QA5_'O43HQBF^9,UIXB<Y*+@T9NNQ%KQGMK&\6\0
M#R[B <-QT/M6U!VC:4E;LSEQ<6YWA%\W1K]3H+3SOL</VC'G;!OQZXYKCG;F
M?+L>E3YN1<^Y-4EA0 4 % !0 4 % !0 4 % !0!4U*R&HZ=-:%]GF 8;&<$'
M(_E6E*?LYJ1C7I>VIN'<Y>T\&3B[4W<T1@4Y(0G+#T]J[YXV/+[JU/)IY9)3
M]]JP[QE>7,=U!;1R,D/E[_E.,G)'^?K2P4(N+D]QYG5G&2@G96%\'7UU)<36
MTCM)"$W@L<[3D#'^?2C&4XI*2W#+*LY2<'JC(UV^NY-8N5>5U$<A5%!P  >*
MZ:%."IJR.+%U:CK23>S.FTF-]:\+&"[D9BV4#GD\'@^_/\JX*S5&O>)ZV'3Q
M.%Y9LSK?P5,+E3/<QF ')"@Y(]/:MY8U6]U:G+#*Y*7O2T.RZ5YA[@4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % %2^TVUU*)8[J+>%.0<X(_&M*=25-WBS&K0A65IH6QT^UT
MV$Q6L6Q2<GDDD_4T5*DJCO)CI4845RP5B&]T33]0F$MS!ND QD,1GZXJH5ZE
M-6BS.KA:59\TUJ78HHX(ECB0(BC 4# %9-MN[.B,5%66P^D,* "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
$"@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g76834sig.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g76834sig.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M^@% $L+2/"C3((Y",LH.<>V: )* "@ H * "@"*YA-Q;M$)I(2?XXR P^F:
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M* (8+&VMI6DBCVLQ)ZD@9.3@=LGGB@"62*.4*)$#!6# $9P1T- #+JW%U;/
MQPKC#<=N] $5]IT5\L0=Y(VB;<CQMM(."#^A- $EI:06-LEO;1B.)!@** (Y
M=,LY[Z*]EMU>XB&$<]O\Y/YT 1W]N]S=V "G9#,96/884@?JPH OT % !0 4
5 % !0 4 % !0 4 % !0 4 % '__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
